Novartis’ Pelacarsen Misses Key Endpoint, Shakes Lp(a) Therapeutic Confidence
Swiss pharmaceutical giant Novartis, in partnership with Ionis Pharmaceuticals, announced that their investigational drug Pelacarsen, designed to reduce lipoprotein(a) [Lp(a)] cholesterol, did not significantly improve cardiovascular outcomes in a critical late-stage trial. The trial results, released on September 5, 2026, triggered a 3% decline in Novartis shares the following Monday.
This setback marks the first time data from a major trial questions the longstanding theory that lowering Lp(a)—a genetically determined lipoprotein linked to elevated cardiovascular risk—can meaningfully reduce heart attacks and strokes. Currently, no treatment targeting Lp(a) has regulatory approval, despite the market potential in the multi-billion dollar range for such therapies.
Understanding Lp(a) and the Drug’s Mechanism
Lp(a), identified in 1963, is a unique lipoprotein whose blood levels are largely governed by genetics, unlike traditional LDL cholesterol which can be influenced by lifestyle factors. Elevated Lp(a) has been shown to more than double cardiovascular risk.
Novartis emphasized that over 8,000 patients in the trial received optimal standard care, yet despite Pelacarsen’s ability to lower Lp(a) levels, it did not translate into a statistically significant reduction in cardiovascular events. Shreeram Aradhye, Novartis’s Chief Medical Officer, noted that full trial data will be shared at an upcoming medical conference, but current findings offer important insights into the complex relationship between Lp(a) reduction and clinical outcomes.
Ripple Effects on Amgen and Eli Lilly
The disappointing results have broader implications beyond Novartis. Competitors Amgen and Eli Lilly, both developing their own Lp(a)-lowering therapies—Olpasiran and Lepodisiran respectively—face heightened scrutiny. Amgen’s clinical program mirrors Pelacarsen’s approach, while Eli Lilly’s candidate targets a wider population, including those not yet diagnosed with cardiovascular disease.
Following the news, Amgen’s shares fell about 5% in after-hours trading, Ionis Pharmaceuticals declined by 10%, and NewAmsterdam Pharma dropped 12%. Analysts suggest that Novartis’ data undermines investor confidence in the entire Lp(a) reduction hypothesis, increasing the onus on upcoming trials to demonstrate stronger Lp(a) lowering and clear clinical benefits.
Market and Analyst Perspectives
Market analysts had long anticipated modest cardiovascular risk reductions from Lp(a) therapies, reflected in the relatively muted share price reaction. Citigroup’s analysts remarked that "although Pelacarsen failed to meet the primary endpoint, the concept that lowering Lp(a) can prevent cardiovascular disease remains unsettled, pending further data to clarify the therapeutic mechanism and trial design factors."
Barclays highlighted that while a 13% risk reduction would have been statistically meaningful, Pelacarsen did not achieve this benchmark. Jefferies pointed out that ongoing advances in optimized standard treatments have lowered cardiovascular event rates overall, making it increasingly difficult and costly to demonstrate added benefits with new drugs.
Continuing Development and Industry Outlook
Given that Amgen and Eli Lilly utilize different molecular approaches, some analysts are cautiously optimistic that alternative therapies could achieve deeper lowering of Lp(a), potentially benefiting patients with extremely high levels. William Blair analysts commented that despite Novartis’ failure, the development landscape for Lp(a) drugs remains challenging but not closed.
With an estimated one-fifth of the global population affected by elevated Lp(a)-associated cardiovascular risk, research and competition in this sector are expected to continue. Upcoming clinical data will be critical in shaping the future of Lp(a) therapeutics and informing regulatory and investor sentiment.